Fish & Richardson was all over the map last year, with appearances in 222 new patent cases in federal courts across the United States, plus a major U.S. Supreme Court win and successful litigation at the International Trade Commission (ITC). The firm also scored two key victories in cases involving the Hatch-Waxman Act, the federal law governing the procedure for bringing generic drugs to market.
Long-term ties with the Mayo Clinic culminated in March’s Supreme Court win in Mayo Collaborative Services v. Prometheus Laboratories Inc. In a 9-0 decision by Justice Stephen Breyer, the Court determined that two patents on Prometheus’ diagnostic test used in the treatment of autoimmune diseases were invalid and not patent-eligible. He wrote that upholding the patents “would risk disproportionately tying up the use of the underlying natural laws.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
